Anavex Life Sciences Corp. (NASDAQ:AVXL) Director Peter. Donhauser Purchases 2,835 Shares

Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) Director Peter D.O. Donhauser acquired 2,835 shares of the stock in a transaction on Friday, June 14th. The stock was bought at an average price of $3.64 per share, with a total value of $10,319.40. Following the transaction, the director now directly owns 5,000 shares of the company's stock, valued at approximately $18,200. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Anavex Life Sciences Price Performance

Shares of Anavex Life Sciences stock traded down $0.05 during midday trading on Monday, reaching $3.72. 93,172 shares of the company's stock traded hands, compared to its average volume of 1,312,158. The stock has a 50 day moving average of $3.99 and a 200-day moving average of $5.50. Anavex Life Sciences Corp. has a 12 month low of $3.25 and a 12 month high of $10.45.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). During the same period in the previous year, the firm earned ($0.17) earnings per share. As a group, equities research analysts forecast that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current year.

Institutional Investors Weigh In On Anavex Life Sciences

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Anavex Life Sciences by 1.2% in the first quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company's stock valued at $22,471,000 after acquiring an additional 54,034 shares during the period. Nwam LLC lifted its holdings in Anavex Life Sciences by 4.8% in the first quarter. Nwam LLC now owns 836,730 shares of the biotechnology company's stock valued at $4,259,000 after acquiring an additional 38,437 shares during the period. Jupiter Asset Management Ltd. lifted its holdings in Anavex Life Sciences by 675.0% in the first quarter. Jupiter Asset Management Ltd. now owns 804,642 shares of the biotechnology company's stock valued at $4,096,000 after acquiring an additional 700,812 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Anavex Life Sciences by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 622,310 shares of the biotechnology company's stock worth $5,794,000 after buying an additional 17,499 shares during the period. Finally, SG Americas Securities LLC raised its stake in shares of Anavex Life Sciences by 14.2% in the fourth quarter. SG Americas Securities LLC now owns 307,568 shares of the biotechnology company's stock worth $2,863,000 after buying an additional 38,155 shares during the period. 31.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Anavex Life Sciences in a research report on Tuesday, June 11th.

Check Out Our Latest Research Report on AVXL

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.

Featured Stories

• Five stocks we like better than Anavex Life Sciences
• The Most Important Warren Buffett Stock for Investors: His Own
• Buy, Sell, or Hold: What to Do with AMC Entertainment Stock?
• Why Invest in High-Yield Dividend Stocks?
• Is the Disney Stock Sell-Off a Prime Buying Opportunity?
• Stock Splits, Do They Really Impact Investors?
• Overbought vs Oversold Stocks: Key Differences and Examples

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Hurry! Buy this stock before the Robinhood traders do! (From Traders Agency) (Ad)

Should you invest $1,000 in Anavex Life Sciences right now?

Before you consider Anavex Life Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.

While Anavex Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here